Bavarian Nordic appoints new president and CEO
Chaplin joined Bavarian Nordic in 1999. He became the company's head of research in 2000 and was appointed executive vice president in 2004. Chaplin led the development program for the IMVAMUNE smallpox vaccine and worked on several successful collaborations on other vaccines with the U.S. government.
Since 2010, Chaplin served as the company's division president of infectious diseases.
"Paul Chaplin is the ideal person to lead our company at this time," Gerard van Odijk, the chairman of the board of Bavarian Nordic, said. "As a member of our executive management team for over a decade. Paul has demonstrated excellent results and leadership at Bavarian Nordic. From his work in early research and development, to building our large-scale manufacturing infrastructure, managing government contracts and optimizing operations in our infectious disease division, and turning it into a profitable business, we welcome the opportunity to have Paul as our CEO."
Chaplin replaces Anders Hedegaard, who served in the position since 2007. Hedegaard is leaving the company to join GN ReSound A/S as its CEO.
Chaplin will be assisted by Hedegaard over the next few weeks to ensure a smooth transition.
"I am very excited about my new role and the opportunity to lead Bavarian Nordic further on the growth track of commercial and clinical success that we have seen to date," Chaplin said. "We have developed into a fully-fledged, integrated business, ready to maximize the potential of new vaccines and cancer immunotherapies in the pipeline, which hold great promise."